Studies Highlight Newly Approved and Novel Multiple Myeloma Treatments

Barbara L. Jones
Published: Friday, Jul 26, 2013
Katja C. Weisel, MD

Katja C. Weisel, MD

Researchers highlighted the latest developments in the treatment of multiple myeloma at the 2013 ASCO Annual Meeting. Noteworthy abstracts included updated data on pomalidomide (Pomalyst), which the FDA recently approved, as well as research involving the promising novel agents daratumumab and elotuzumab.

New Standard of Care in Relapsed/Refractory MM

Pomalidomide plus low-dose dexamethasone “should become the standard of care for patients with relapsed/refractory multiple myeloma (MM) after treatment with lenalidomide and bortezomib,” said Katja C. Weisel, MD, associate professor at University Hospital Tuebingen in Germany, reflecting the views of an international group of investigators taking part in the large MM-003 trial.1

On February 8, 2013, the FDA approved oral pomalidomide for the treatment of patients with MM who have received at least two prior therapies, including lenalidomide and bortezomib, and who have had disease progression on or within 60 days of completion of the last therapy.

CD38 Monoclonal Antibody Yields “Unprecedented” Early-Stage Data

The investigational monoclonal antibody (mAb) daratumumab targets the CD38 molecule, which is highly expressed on the surface of multiple myeloma (MM) cells. Daratumumab has been shown to have broad-spectrum cytotoxic activity; it acts by mediating killing of CD38-expressing tumor cells via antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and apoptosis.

Sagar Lonial, MD

Sagar Lonial, MD

In early May, the FDA granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with MM who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or for patients who are double-refractory to both classes of drugs.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Articles
Blogs
Conference Coverage
OncLive TV
Peer Exchange
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
 
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.
 
x